Xeris Biopharma Holdings, Inc.
XERSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Xeris Biopharma Holdings, Inc. (XERS) is listed under Drug Manufacturers - Specialty & Generic. Valued at $1.55B, XERS is a small-cap name in its sector. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Market Cap
$1.55B
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
21.74
EPS (TTM)
$-0.10
EPS (Fwd)
$0.39
ROE
—
ROA
6.1%
Cash
$121.7M
Total Debt
$289.4M
Free CF
$52.5M
52W Change
9.2%
Annual Financials
Cash vs Debt
Where XERS stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, XERS finished 21.29% above its 150-day moving average ($6.95) and 20.09% above its 200-day moving average ($7.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XERS overbought or oversold?
At the September 2, 2026 close, XERS's RSI(14) was 48.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, XERS has $121.7M in cash with $289.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $52.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $110.2M (2022) to $291.8M (2025), reflecting a 165% increase over the period.
Investors considering Xeris Biopharma Holdings, Inc. should weigh the typical risks associated with XERS's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing XERS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.